title: Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.
abstract: OBJECTIVE
  Lack of appropriate tumor models that reliably predict response to anticancer agents remains a major deficiency in the clinical practice of personalized cancer therapy. The aim of our study was to establish a patient-derived tumor tissue (PDTT) xenograft model of gastric carcinoma for personalized cancer therapeutic regimen selection and testing of novel molecularly targeted agents.
  
  
  METHODS
  Patient-derived tumor tissue of primary gastric carcinoma was used to create the xenograft model. After 11 weeks, xenografts were harvested for serial transplantation. H&E staining, immunohistochemical staining and Western blotting were used to determine biological stability of the xenograft during serial transplantation compared with the original tumor tissue. Drug sensitivities of the xenograft to bevacizumab (Avastin), FP3 and cetuximab were evaluated.
authors.affiliation: Department of Surgical Oncology, Zhejiang University, Zhejiang, China.
authors.forename: Ketao
authors.initials: K
authors.lastname: Jin
authors.forename: Kuifeng
authors.initials: K
authors.lastname: He
authors.forename: Na
authors.initials: N
authors.lastname: Han
authors.forename: Guangliang
authors.initials: G
authors.lastname: Li
authors.forename: Haohao
authors.initials: H
authors.lastname: Wang
authors.forename: Zhenzhen
authors.initials: Z
authors.lastname: Xu
authors.forename: Haiping
authors.initials: H
authors.lastname: Jiang
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Lisong
authors.initials: L
authors.lastname: Teng
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D000068258:Bevacizumab; D015153:Blotting, Western; D000068818:Cetuximab; D006801:Humans; D008297:Male; D051379:Mice; D008875:Middle Aged; D057285:Precision Medicine; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D013274:Stomach Neoplasms / Q000473:pathology* / Q000628:therapy*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C557495:FP3 VEGF receptor Fc-fusion protein; D011993:Recombinant Fusion Proteins; D000068258:Bevacizumab; D000068818:Cetuximab